Vigilant Biosciences Raises $10.5M in Series B Round

Vigilant Biosciences Raises $10.5M in Series B Round July 11, 2016 Vigilant Biosciences, an oral cancer testing company, announced that it has raised a total of $10.5 million in Series B financing. The second phase of the Series B round brought in $5 million and investors in this phase included White Owl Capital Partners, venVelo

Vigilant Raises $5M to Commercialize Oral Cancer Test

Vigilant Raises $5M to Commercialize Oral Cancer Test July 11, 2016 Vigilant Biosciences has raised $5 million to commercialize OncAlert, its oral cancer detection test. Vigilant has received $12.5 million in total funding, including most recently a round of $5 million in Series B funding. The proceeds will be used for the international commercialization of

Vigilant Biosciences Announces Three New OncAlert Distribution Agreements for Europe, Africa, and Latin America

Vigilant Biosciences Announces Three New OncAlert Distribution Agreements for Europe, Africa, and Latin America June 15, 2016 The new OncAlert agreements will further expand Vigilant Biosciences’ reach and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the diagnosis and treatment of oral cancer. Vigilant Biosciences Inc., an innovator and

From the Editor: Liquefaction, Dx Style

From the Editor: Liquefaction, Dx Style June 7, 2016 When technologies have matured to the point of market readiness, it can be hard to keep track of the many new products that suddenly become available to the marketplace. This spring, after many months of anticipation, early FDA approvals hint that the floodgates for so-called “liquid

Oral Rinse Test Picks Up Early-Stage Oral Cancer

Oral Rinse Test Picks Up Early-Stage Oral Cancer June 7, 2016 An inexpensive oral rinse test has been shown to distinguish head and neck cancer patients from people who are at high risk for the disease, and offers hope that the diagnosis of oral cancer could be made at a much earlier stage than it

Early Detection of Head and Neck Cancer Gets a Boost: Vigilant Biosciences Launches First-of-its-kind OncAlert Labs OraMark Test in the United States

Early Detection of Head and Neck Cancer Gets a Boost: Vigilant Biosciences Launches First-of-its-kind OncAlert Labs OraMark Test in the United States June 6, 2016 First quantitative laboratory-developed test to accurately measure a tumor-initiating and stem cell–associated biomarker for head and neck cancer in an oral rinse Vigilant Biosciences Inc. (Fort Lauderdale, Florida), a developer

Fort Lauderdale Biotech Company Launches Oral Cancer Test

Fort Lauderdale Biotech Company Launches Oral Cancer Test May 31, 2016 Vigilant Biosciences is making its oral rinse test available to dentists in the United States, the Fort Lauderdale startup company said Tuesday. The laboratory test is designed to measure a biomarker for oral cancer detection at its earliest stages. The OncAlert Labs OraMark Test

Vigilant Creates New Clinical Officer Position

Vigilant Creates New Clinical Officer Position May 25, 2016 Vigilant Biosciences has appointed Michael Donovan, MD, PhD, as the its new chief clinical officer. Dr. Donovan will be part of the executive management team and is responsible for advancing Vigilant’s oral cancer product line. He received his medical degree from the University of Medicine and

Vigilant Biosciences Receives CE Mark for OncAlert Oral Cancer Rapid Test

Vigilant Biosciences Receives CE Mark for OncAlert Oral Cancer Rapid Test May 13, 2016 The CE mark, a mandatory conformity marking in the European Union (EU), will allow the product to be sold in the 28 countries of the EU and Norway, Iceland, Liechtenstein and Switzerland. Vigilant Biosciences Inc. has announced that it has CE

Vigilant Biosciences Cleared to Launch its Oral Cancer Test Across Europe

Vigilant Biosciences Cleared to Launch its Oral Cancer Test Across Europe May 4, 2016 Vigilant Biosciences, an early-stage Fort Lauderdale-based company that develops solutions that aid in the early detection and intervention of cancer, announced that it has CE Marked its OncAlert Oral Cancer RAPID Test, meaning it can market the product in the 28

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2